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Redox imbalance and persistent inflammation are the underlying causes of
most chronic diseases. Mammalian cells have evolved elaborate mechanisms
for restoring redox homeostasis and resolving acute inflammatory
responses. One prominent mechanism is that of inducing the expression of
antioxidant, anti-inflammatory and other cytoprotective proteins, while
also suppressing the production of pro-inflammatory mediators, through
the activation of transcription factor nuclear factor-erythroid 2 p45-related
factor 2 (NRF2). At homeostatic conditions, NRF2 is a short-lived protein,
which avidly binds to Kelch-like ECH-associated protein 1 (KEAP1).
KEAP1 functions as (i) a substrate adaptor for a Cullin 3 (CUL3)-based E3
ubiquitin ligase that targets NRF2 for ubiquitination and proteasomal degra-
dation, and (ii) a cysteine-based sensor for a myriad of physiological and
pharmacological NRF2 activators. Here, we review the intricate molecular
mechanisms by which KEAP1 senses electrophiles and oxidants. Chemical
modification of specific cysteine sensors of KEAP1 results in loss of NRF2-
repressor function and alterations in the expression of NRF2-target genes
that encode large networks of diverse proteins, which collectively restore
redox balance and resolve inflammation, thus ensuring a comprehensive
cytoprotection. We focus on the cyclic cyanoenones, the most potent NRF2
activators, some of which are currently in clinical trials for various
pathologies characterized by redox imbalance and inflammation.1. Introduction
All living organisms are vulnerable to various chemical stressors derived from
endogenous and exogenous sources, such as reactive oxygen species (ROS),
reactive nitrogen species (RNS) and reactive lipid species (RLS), which play
important roles in cell signalling, but when produced in excess lead to
oxidative stress. Oxidation–reduction (redox) reactions are common in biology,
and the maintenance of redox homeostasis is vital for the correct functioning of
most biological processes [1]. Oxidative stress occurs when there is an excess of
oxidants, and the antioxidants are insufficient for restoring the intracellular
redox balance [2]. Some examples of sources of exogenous oxidative stressors
are environmental pollutants, ultraviolet (UV) and ionizing radiation, and
genotoxic agents. Endogenous stressors, usually produced intracellularly, are
derived from metabolic processes such as mitochondrial respiration and inflam-
mation. Exposure to these chemically reactive species promotes cellular
macromolecular damage. Chronic oxidative stress has been implicated in the
development and exacerbation of neurodegenerative diseases [3,4], cancer
[5,6], diabetes [7,8], autoimmune [9], cutaneous [10–12], pulmonary [13,14]
and cardiovascular [14,15] diseases, infection [16], inflammation [17], as well
as aging [18–20]. Cells have evolved several mechanisms to combat these
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Figure 1. (a) Domain structure of human NRF2. There are seven NRF2-ECH (Neh) domains found within NRF2. The N-terminal Neh2 domain contains the KEAP1
binding motifs DLG and ETGE. The Neh4 and 5 domains within the transcription factor are required for its transactivation and the proteins that have exhibited
binding to this region are CREB (cAMP responsive element binding protein) binding protein (CBP), AXIN1, silencing mediator of retinoic acid and thyroid hormone
receptor (SMRT1), Receptor-associated coactivator 3 (RAC3), nuclear matrix protein (NRP/B), casein kinase 2 (CK2), Brahma-related gene 1 (BRG1) and mediator
complex subunit 16 (MED16). The Neh7 domain found in the middle of the NRF2 protein has been shown to interact with retinoid X receptor alpha (RXRα)
as well as retinoic acid receptor alpha (RARα). Two motifs, DSGIS and DSAPGS are found within the Neh6 domain, and are important for the binding of β-
TrCP to facilitate NRF2-degradation, where the binding is promoted upon glycogen synthase kinase β (GSK3-β)-mediated phosphorylation of the DSGIS motif.
C-Jun N-Terminal Kinase (JNK) binds to the Neh6 domain and phosphorylates S335. The Neh1 domain comprises of the DNA-binding motif and the binding
region for the sMAF proteins. The carboxy-terminal Neh3 domain is also important for transactivation of NRF2 and chromodomain helicase DNA binding protein
6 (CHD6) interacts with this domain. (b) Domain structure of human KEAP1. The KEAP1 protein is a substrate adaptor for the CUL3-based E3 ligase, and is sectioned
into five domains: (1) N-terminal region (NTR); (2) Broad complex, tramtrack, and Bric à Brac (BTB) domain allows for the homodimerization of KEAP1 monomers as
well as CUL3 binding; (3) Intervening region (IVR); (4) Kelch domain (KELCH) is a structure consisting of a six-bladed β-propeller, where one KELCH subunit within
the KEAP1 homodimer binds to the DLG motif and the other binds to the ETGE motifs found within the Neh2 domain of NRF2; and (5) C-terminal region (CTR). The
black vertical lines represent the positions of the 27 cysteine residues present within the protein. Cartoon and surface representations of the BTB (pale pink) (PDB ID:
4CXI), IVR (pale yellow) (modelled) and KELCH (pale blue) (PDB ID: 5WFV) were drawn with UCSF ChimeraX software using X-Crystallographic images deposited into
the Protein Data Bank (rscb.org) or modelled using the web-based I-TASSER platform.
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2relentless chemical insults in order to reinstate the redox
homeostasis. The activation of the KEAP1/NRF2/ARE path-
way is one such mechanism, which orchestrates the
upregulation of antioxidant, anti-inflammatory and other
cytoprotective proteins.2. The NRF2/KEAP1/ARE cytoprotective
pathway
Under homeostatic conditions, the transcription factor
nuclear factor erythroid-2 p45-related factor 2 (NRF2)
(figure 1a), is continuously ubiquitinated and targeted for
26S proteasomal degradation by its negative regulator
Kelch-like (ECH)-associated protein 1 (KEAP1) (figure 1b),
which is a substrate adaptor for the Cullin 3 (CUL3)-ring
box 1 (RBX1) E3-ubiquitin ligase system [21]. Electrophiles
from endogenous and exogenous sources or other small mol-
ecules (termed inducers) which activate NRF2 are able to do
so via inactivating KEAP1 by reacting with its cysteine(s)residues or by disrupting the KEAP1:NRF2 protein–protein
interaction (PPI) interface [22,23]. Consequently, KEAP1 is
unable to target the transcription factor for degradation. The
interactions between KEAP1 and NRF2 and the effect of indu-
cers on NRF2 stabilization can be visualized by the imaging of
live cells expressing KEAP1 and NRF2, each fused to a fluor-
escent protein [24,25]. Following KEAP1 inactivation, the
newly synthesized or free NRF2 is able to accumulate and
translocate into the nucleus where it heterodimerizes with a
small musculoaponeurotic fibrosarcoma (sMAF) protein and
binds to the antioxidant response elements (ARE) with the
consensus sequence 50-TGACxxxGC-30 found in the promo-
ters of its target genes [21]. The 605-amino acid long NRF2
protein belongs to the family of the Cap’n’Collar (CnC)
basic leucine zipper (bZIP) transcription factors, and is
composed of seven NRF2-ECH (Neh) domains which are
highly conserved (figure 1a). The N-terminally lying Neh2
domain of NRF2 contains two KEAP1 (low- and high-affinity)
binding motifs, which are the sequences DLG and ETGE,
respectively [26].
royalsocietypublishing.org/journal/rsob
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32.1. NRF2-mediated antioxidant effects
Together, the NRF2 target genes (over 250) are involved in
mounting a cellular defence response by encoding a large net-
work of proteins, some of which catalyse phase I, II and III
cytoprotective detoxification reactions, while others have anti-
oxidant and anti-inflammatory properties [27]. NRF2 controls
the cellular redox homeostasis by regulating key enzymes and
proteins involved in processes such as the synthesis, utilization
and regeneration of glutathione (GSH), thioredoxin (TXN), per-
oxiredoxin and NADPH production [28]. The activity of NRF2
is a major determining factor of the cellular redox state.
GSH is an essential thiol-based intracellular tripeptide
that plays a vital role in the defence against cellular oxidative
stress through its ability to neutralize ROS/RNS as well as
electrophilic species [29]. Perturbed glutathione homeostasis
has been implicated in numerous pathological conditions
[30,31]. NRF2 regulates the gene expression of the catalytic
subunit GCLC and the modifier subunit GCLM of
γ-glutamate-cysteine ligase (GCL), the enzyme catalysing the
rate-limiting step in the GSH biosynthesis [32], as well as the
gene expression of the cystine/glutamate antiporter (SLC7A11,
system xc−) [33] that is responsible for the import of cystine,
which in turn is converted to cysteine, a GSH precursor. The
fluxofglutamine into anabolic pathways is enhancedundercon-
ditions of NRF2 activation [34] thus providing glutamate, the
second GSH precursor; of note, glutamate is also necessary for
the import of cystine by system xc−. The transporter SLC6A9,
another NRF2-regulated gene, provides the third GSH precur-
sor, glycine [35]. In addition to the biosynthesis of GSH, NRF2
also regulates the regeneration of GSH. The transcription
factor controls the expression of glutathione peroxidase (GPX),
which detoxifies peroxides to produce oxidized glutathione
(GSSG). In turn, GSSG is a substrate for the NRF2-target gluta-
thione reductase (GSR), which regenerates GSH from GSSG
using NADPH as a hydride donor. Importantly, NRF2 is also
involved in the regulationof cellularNADPHlevels bycontrolling
the gene expression of the four main enzymes involved in the
generation of NADPH: isocitrate dehydrogenase 1 (IDH1),
6-phosphogluconate dehydrogenase (PGD), glucose-6-phosphate
dehydrogenase (G6PD) and malic enzyme 1 (ME1) [34,36].
The role of NRF2 in the biosynthesis and maintenance of
GSH is particularly important in the brain [37,38], and may
also affect the metabolic glutamate–glutamine cycle that
allows the inter-cellular exchange of these amino acids between
neurons and astrocytes [39]. During neuronal development,
expression of NFE2L2 (the gene encoding NRF2) is repressed
by promoter methylation [40], and NRF2 activity in astrocytes
is critical for neuronal protection against oxidative stress [41].
In rapidly proliferating cells, such as cancer cells, NRF2 acti-
vation channels glucose through the pentose phosphate
pathway [34], a major source of reducing equivalents for
GSH regeneration, but also increases consumption of gluta-
mate for GSH biosynthesis and glutamate secretion by
system xc− [42].
2.2. NRF2-mediated anti-inflammatory effects
In addition to antioxidant, the activation of NRF2 has anti-
inflammatory effects, which have been consistently observed
in cellular and animal models, as well as in human intervention
trials with pharmacological NRF2 activators. Thus, a recent
analysis ofperipheral bloodmononuclear cells (PBMCs) isolatedfrom human subjects following intervention with sulforaphane,
a classical NRF2 activator, reported an increase in the expression
of NRF2-target genes (i.e. NQO1, HO1, AKR1C1), which was
accompanied by a decrease in inflammatory markers (i.e. IL-6,
TNFα, IL-1β, COX2) [43]. NRF2 is critical for the resolution
of inflammation. The endogenous mildly electrophilic anti-
inflammatory mitochondrial immunometabolite itaconate,
whichaccumulates tomillimolarconcentrationsduringthemeta-
bolic reprogramming in activated macrophages [44,45], is an
NRF2 activator. In turn, NRF2 represses the expression of pro-
inflammatory cytokines and the type I interferon (IFN) response,
promoting the resolution of inflammation [45–49]. Interestingly,
NRF2 is also important for the execution of inflammation.
Itaconate is downregulated in dysfunctional macrophages from
hypercholesterolemic mice, and the levels of NRF2 and the
expression of its target genes are lower in lipopolysaccharide
(LPS)-stimulated macrophages isolated from mice fed high-
fat diet (HFD) compared to standard fat diet (SFD) [50]. These
findings illustrate that systemic metabolic changes can suppress
NRF2 and consequently interfere with metabolic reprogram-
ming in immune cells, which is necessary for their effector
functions.
Thus, the activation of NRF2 is an attractive therapeutic
strategy to combat diseases characterized by chronic oxidative
stress and inflammation as it provides a multi-targeted
approach [51,52]. Indeed, in recent years the pharmaceutical
industry has invested heavily in the development of pharmaco-
logical modulators of the KEAP1/NRF2/ARE pathway, and
there are currently more than 15 ongoing clinical trials as
well as a number of compounds undergoing preclinical testing
for various disease indications [23,53].3. KEAP1
KEAP1 is a highly conserved cysteine-rich 624-amino acid
protein sharing approximately 92% sequence homology
among the mammalian species (figure 2). The existence of
KEAP1 was predicted in the 1980s, more than a decade before
its discovery. Following a series of extensive structure-activity
studies using quantitative chemical biology approaches, Paul
Talalay and his associates observed that numerous structurally
diverse inducers of the cytoprotective enzymes NAD(P)H:qui-
none oxidoreductase (NQO1) and glutathione S-transferases
(GSTs) have a common chemical property, namely sulfhydryl
reactivity. This seminal discovery rationalized the perplexing
lack of structural similarity among inducers, and led to the
explicit suggestion that the primary cellular sensor with
which inducers react is a protein endowed with highly reactive
cysteines [54,55]. The identification of KEAP1 as a negative reg-
ulator of NRF2 by Masayuki Yamamoto and his colleagues in
1999 [56] immediately turned attention to the cysteine residues
of KEAP1. Human KEAP1 has 27 cysteines, whereas mouse
KEAP1 has 25, nine of which (red boxes in figure 2) are flanked
by basic amino acids. Cysteines are unique amino acids due to
their sulfhydryl (thiol) functional group that performs various
functions, including: (1) forming intra- and intermolecular
covalent bonds with other cysteine thiols, (2) binding to
metals and metalloids, and (3) undergoing reversible or
irreversible oxidation upon reacting with oxidants [57]. The
pKa value of cysteine (represented by the balance between the
thiol and the thiolate anion) indicates its reactivity [58]. The
lower the pKa value, where the formation of the thiolate anion
SP|Q14145|KEAP1_HUMAN  MQPDPRPSGAGACCRFLPLQSQCPEGAGDAVMYASTECKAEVTPSQHGNRTFSYTLEDHT 60
SP|Q9Z2X8|KEAP1_MOUSE  MQPEPKLSGAPRSSQFLPLWSKCPEGAGDAVMYASTECKAEVTPSQDGNRTFSYTLEDHT 60
SP|P57790|KEAP1_RAT    MQPEPKPSGAPRSSQFLPLWSKCPEGAGDAVMYASTECKAEVTPSQDGNRTFSYTLEDHT 60
SP|Q684M4|KEAP1_PIG    MQPEPRPSGAGAHTQFLPLRSQRPEGAGDTVMYASTECKAEVTPSQHGNRTFSYTLEDHT 60
SP|Q5R774|KEAP1_PONAB  MQPDPRPSGAGACSRFLPLRSQCPEGAGDAVMYASTECKAEVTPSQHGNRTFSYTLEDHT 60
TR|H2QFB9|H2QFB9_PANTR MQPDPRPSGAGACCRFLPLQSQCPEGAGDAVMYASTECKAEVTPSQHGNRTFSYTLEDHT 60
***:*: ***    :**** *: ******:****************.*************
SP|Q14145|KEAP1_HUMAN  KQAFGIMNELRLSQQLCDVTLQVKYQDAPAAQFMAHKVVLASSSPVFKAMFTNGLREQGM 120
SP|Q9Z2X8|KEAP1_MOUSE  KQAFGVMNELRLSQQLCDVTLQVKYEDIPAAQFMAHKVVLASSSPVFKAMFTNGLREQGM 120
SP|P57790|KEAP1_RAT    KQAFGIMNELRLSQQLCDVTLQVKYEDIPAAQFMAHKVVLASSSPVFKAMFTNGLREQGM 120
SP|Q684M4|KEAP1_PIG    KQAFGIMNELRLSQQLCDVTLQVKYEDAPAAQFMAHKVVLASSSPVFKAMFTNGLREQGM 120
SP|Q5R774|KEAP1_PONAB  KQAFGIMNELRLSQQLCDVTLQVKYQDAPAAQFMAHKVVLASSSPVFKAMFTNGLREQGM 120
TR|H2QFB9|H2QFB9_PANTR KQAFGIMNELRLSQQLCDVTLQVKYQDAPAAQFMAHKVVLASSSPVFKAMFTNGLREQGM 120
*****:*******************:* ********************************
SP|Q14145|KEAP1_HUMAN  EVVSIEGIHPKVMERLIEFAYTASISMGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLD 180
SP|Q9Z2X8|KEAP1_MOUSE  EVVSIEGIHPKVMERLIEFAYTASISVGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLD 180
SP|P57790|KEAP1_RAT    EVVSIEGIHPKVMERLIEFAYTASISVGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLD 180
SP|Q684M4|KEAP1_PIG    EVVSIEGIHPKVMERLIEFAYTASISMGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLD 180
SP|Q5R774|KEAP1_PONAB  EVVSIEGIHPKVMERLIEFAYTASISMGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLD 180
TR|H2QFB9|H2QFB9_PANTR EVVSIEGIHPKVMERLIEFAYTASISMGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLD 180
**************************:*********************************
SP|Q14145|KEAP1_HUMAN  PSNAIGIANFAEQIGCVELHQRAREYIYMHFGEVAKQEEFFNLSHCQLVTLISRDDLNVR 240
SP|Q9Z2X8|KEAP1_MOUSE  PSNAIGIANFAEQIGCTELHQRAREYIYMHFGEVAKQEEFFNLSHCQLATLISRDDLNVR 240
SP|P57790|KEAP1_RAT    PSNAIGIANFAEQIGCTELHQRAREYIYMHFGEVAKQEEFFNLSHCQLATLISRDDLNVR 240
SP|Q684M4|KEAP1_PIG    PSNAIGIANFAEQIGCAELHQRAREYIYMHFGEVAKQEEFFNLSHCQLVTLISRDDLNVR 240
SP|Q5R774|KEAP1_PONAB  PSNAIGIANFAEQIGCVELHQRAREYIYMHFGEVTKQEEFFNLSHCQLVTLISRDDLNVR 240
TR|H2QFB9|H2QFB9_PANTR PSNAIGIANFAEQIGCVELHQRAREYIYMHFGEVAKQEEFFNLSHCQLVTLISRDDLNVR 240
****************.*****************:*************.***********
SP|Q14145|KEAP1_HUMAN  CESEVFHACINWVKYDCEQRRFYVQALLRAVRCHSLTPNFLQMQLQKCEILQSDSRCKDY 300
SP|Q9Z2X8|KEAP1_MOUSE  CESEVFHACIDWVKYDCPQRRFYVQALLRAVRCHALTPRFLQTQLQKCEILQADARCKDY 300
SP|P57790|KEAP1_RAT    CESEVFHACIDWVKYDCPQRRFYVQALLRAVRCHALTPRFLQTQLQKCEILQADARCKDY 300
SP|Q684M4|KEAP1_PIG    CESEVFHACINWVKYDCEQRRFYVQALLRAVRCHSLTPHFLQMQLQKCEILQSDSRCKDY 300
SP|Q5R774|KEAP1_PONAB  CESEVFHACINWVKYDCEQRRFYVQALLRAVRCHSLTPNFLQMQLQKCEILQSDSRCKDY 300
TR|H2QFB9|H2QFB9_PANTR CESEVFHACINWVKYDCEQRRFYVQALLRAVRCHSLTPNFLQMQLQKCEILQSDSRCKDY 300
**********:****** ****************:***.*** *********:*:*****
SP|Q14145|KEAP1_HUMAN  LVKIFEELTLHKPTQVMPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQV 360
SP|Q9Z2X8|KEAP1_MOUSE  LVQIFQELTLHKPTQAVPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSNGSWLRLADLQV 360
SP|P57790|KEAP1_RAT    LVQIFQELTLHKPTQAVPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSNGSWLRLADLQV 360
SP|Q684M4|KEAP1_PIG    LVKIFQELTLHKPTQVMPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQV 360
SP|Q5R774|KEAP1_PONAB  LVKIFEELTLHKPTQVMPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQV 360
TR|H2QFB9|H2QFB9_PANTR LVKIFEELTLHKPTQVMPCRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQV 360
**:**:*********.:*******************************:*:*********
SP|Q14145|KEAP1_HUMAN  PRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGV 420
SP|Q9Z2X8|KEAP1_MOUSE  PRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCASMSVPRNRIGVGV 420
SP|P57790|KEAP1_RAT    PRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCASLSVPRNRSGGGV 420
SP|Q684M4|KEAP1_PIG    PRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGV 420
SP|Q5R774|KEAP1_PONAB  PRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGV 420
TR|H2QFB9|H2QFB9_PANTR PRSGLAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGV 420
*********************************************** :****** * **
SP|Q14145|KEAP1_HUMAN  IDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDG 480
SP|Q9Z2X8|KEAP1_MOUSE  IDGHIYAVGGSHGCIHHSSVERYEPERDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDG 480
SP|P57790|KEAP1_RAT    IDGHIYAVGGSHGCIHHSSVERYEPDRDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDG 480
SP|Q684M4|KEAP1_PIG    IDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDG 480
SP|Q5R774|KEAP1_PONAB  IDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDG 480
TR|H2QFB9|H2QFB9_PANTR IDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFDG 480
*****************.*******:**********************************
SP|Q14145|KEAP1_HUMAN  TNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNSVERYDVE 540
SP|Q9Z2X8|KEAP1_MOUSE  TNRLNSAECYYPERNEWRMITPMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNSVERYDVE 540
SP|P57790|KEAP1_RAT    TNRLNSAECYYPERNEWRMITPMNTIRSGAGVCVLHSCIYAAGGYDGQDQLNSVERYDVE 540
SP|Q684M4|KEAP1_PIG    TNRLNSAECYYPERNEWRMITPMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNSVERYDVE 540
SP|Q5R774|KEAP1_PONAB  TNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNSVERYDVE 540
TR|H2QFB9|H2QFB9_PANTR TNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNSVERYDVE 540
********************* **************.***********************
SP|Q14145|KEAP1_HUMAN  TETWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSG 600
SP|Q9Z2X8|KEAP1_MOUSE  TETWTFVAPMRHHRSALGITVHQGKIYVLGGYDGHTFLDSVECYDPDSDTWSEVTRMTSG 600
SP|P57790|KEAP1_RAT    TETWTFVASMKHRRSALGIAVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRLTSG 600
SP|Q684M4|KEAP1_PIG    TETWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSG 600
SP|Q5R774|KEAP1_PONAB  TETWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSG 600
TR|H2QFB9|H2QFB9_PANTR TETWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSG 600
******** *:*:******:****:**********************:********:***
SP|Q14145|KEAP1_HUMAN  RSGVGVAVTMEPCRKQIDQQNCTC 624
SP|Q9Z2X8|KEAP1_MOUSE  RSGVGVAVTMEPCRKQIDQQNCTC 624
SP|P57790|KEAP1_RAT    RSGVGVAVTMEPCRKQIDQQNCTC 624
SP|Q684M4|KEAP1_PIG    RSGVGVAVTMEPCRKQIDQQNCTC 624
SP|Q5R774|KEAP1_PONAB  RSGVGVAVTMEPCRKQIDQQNCTC 624
TR|H2QFB9|H2QFB9_PANTR RSGVGVAVTMEPCRKQIDQQNCTC 624
************************
amino acid sequence
identity amongst these
species is 92%
Figure 2. Amino acid sequence alignment of various mammalian KEAP1. Alignment performed using the web-based Clustal Omega program found within uniprot.org.
The Uniprot IDs are listed. Q14145 (human), Q9Z2X8 (mouse), P57790 (rat), Q684M4 (pig), Q5R774 (orangutan), H2QFB9 (chimpanzee). The cysteine residues are high-
lighted in yellow and the cysteine residues which have neighbouring basic amino acids are boxed in red. The amino acid sequence identity among these species is 92%.
royalsocietypublishing.org/journal/rsob
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4is favoured, the cysteine reactivity increases. The presence of
basic amino acids in close proximity to a cysteine decreases
the pKa, hence increasing its reactivity [59,60]. The identification
of highly reactive cysteines within KEAP1 that serve as inducer
sensors [61] solved the puzzling fact that many inducers are
active at sub-micromolar concentrations despite the millimolar
intracellular concentrations of glutathione.3.1. KEAP1 structure and its cysteine sensors
KEAP1 is a homodimeric protein belonging to the BTB (Broad
complex, Tramtrack, Bric-á-brac)-Kelch family of proteins,
which are named Kelch-like 1 to 42 (KLHL1–42). All members
of this family are able to bind to CUL3 through their BTB
domain (figure 1b). The BTB domain is necessary for KEAP1
royalsocietypublishing.org/journal/rsob
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5homodimerization, and it has been reported that mutation of
S104 to an alanine residue prevents its homodimerization
and causes NRF2 accumulation in the nucleus [62]. There are
three cysteines present in the KEAP1 BTB domain, C77, C151
and C171. Single mutants of each of the cysteines in the BTB
domain to a serine behave like the wild-type (WT) KEAP1
in terms of their ability to repress NRF2-mediated gene
expression [63]. C151 is the most well characterized in the lit-
erature. Under basal conditions, the KEAP1 C151S mutant is
able to mediate the degradation of NRF2, similarly to the WT
protein [63–65]. Zhang et al. found that the BTB domain of
KEAP1 protected KEAP1 from ubiquitin-mediated degra-
dation [66]. Interestingly, it has been shown by several
groups that under basal conditions, when subjected to SDS-
polyacrylamide gel electrophoresis (PAGE), WT KEAP1
migrates as two distinct species, one at approximately 65 kDa
and the other at 130 kDa and that the slower migrating species
does not appear within the C151S mutant [63,67]. Zhang and
colleagues suggested that the slow migrating species of
KEAP1 is due to posttranslational modifications occurring on
the protein, as the mutation of C151S prevents its occurrence.
We have observed a similar effect following treatment of cells
with the double Michael acceptor dibenzylidene acetone
(DBA) (S.D.N. 2016, unpublished observations). Fourquet
et al. have shown that the intensity of this slower migrating
KEAP1 species, which is resistant to reducing agents, is
increased upon exposure to oxidants and nitrosative agents.
These authors subsequently exposed lysates from induced
cells to the reducing agent β-mercaptoethanol and observed a
complete reduction in the intensified slower migrating species
of KEAP1 hence suggesting that this species mainly consists of
the oxidized form of KEAP1 [67]. Most recently, C151 from
one subunit of the KEAP1 dimer was shown to form a methyli-
midazole crosslink with R135 from the second subunit upon
accumulation of the reactivemetabolite methylglyoxal, the con-
centration of which is increased in the plasma of diabetic
patients [68]. In all cases, these post-translational modifications
of C151 result in dimerization ofKEAP1, accumulation ofNRF2
and activation of the NRF2-driven cytoprotective transcrip-
tional program. Of note, methylglyoxal is a precursor of
highly damaging advanced glycation end-products, and
NRF2 regulates the expression of glyoxalase 1, the enzyme
that detoxifies methylglyoxal, thus protecting against
glycation [69].
The cysteine residues of KEAP1, for which chemical modi-
fications by various electrophiles and oxidants have been either
demonstrated directly or implicated based on mutagenesis
analyses, are summarized in table 1. Some of the well-known
NRF2 inducers that modify C151 are the isothiocyanate sulfor-
aphane (SFN), the alkylating agent iodoacetamide (IAA),
tert-butyl hydroquinone (tBHQ) and diethylmaleate (DEM)
[64,65,73,92]. In 2010, using molecular modelling, McMahon
et al. postulated that the reactivity of C151 in KEAP1 was due
to the presence of five basic amino acid residues (H129, K131,
R135, K150 and H154) located in close spatial proximity to
C151 [64]. These five basic amino acids possess the ability to
deprotonate the thiol group within C151, thereby, lowering
its pKa. This results in the thiol group of C151 to exist as an
anion under physiological pH conditions. Indeed, the authors
showed that KEAP1 bearing the triple mutations K131M,
R135M and K150M, lost the ability to sense electrophiles that
specifically targeted C151 [64]. The crystal structure of the
BTB domain of KEAP1 with the triterpenoid CDDO wassolved in 2014 and deposited in the Protein Data Bank
(rscb.org) with the accession number 4CXI [72]. We measured
the distances of the 5 positively charged amino acids men-
tioned that were adjacent to C151 and found that R135 had
the closest proximity to C151 with a distance of 3.6 angstroms
(Å) (figure 3), which further supports the findings reported by
McMahon and colleagues [64].
To date, there is no crystal structure of the intervening (IVR)
domain of KEAP1 (aa 180 to 315) available. The KEAP1 IVR
domain, flanked by the N-terminal BTB domain and the
Kelch domain at the C-terminus, contains 8 cysteine residues
(C196, C226, C241, C249, C257, C273, C288 and C297), of
which, C273 and C288 are best characterized. Exposure to elec-
trophiles or alkylating agents targeting the cysteines within the
IVR domain, predominantly C273 and C288, leads to the inac-
tivation of KEAP1 and subsequent activation of NRF2
[61,93,94]. Single or double mutations of C273 or C288 to
serine or alanine render KEAP1 inactivewith respect to its abil-
ity to repress and target for degradationNRF2 [63,64,93,95,96].
Since these C273S/A and C288S/A mutants inactivated
KEAP1, they presented a difficulty to study the electrophiles
that could potentially target these cysteines. By systematically
mutating these cysteines, Saito and colleagues showed that
single or double mutation of C273 and C288 to tryptophan
or glutamic acid did not impede the KEAP1-mediated repres-
sion and degradation of NRF2 hence allowing to precisely
identify electrophiles that are sensed by either or both of
these cysteines [65]. In the report published by Saito et al. the
authors showed that 15-deoxy-Δ12,14-prostaglandin J2 (15d-
PGJ2) is sensed specifically by C288, extending the earlier
observations by Levonen et al. who recognized the importance
of cysteine thiols within KEAP1 for sensing electrophilic lipids
[95]. We performed molecular modelling of the amino acid
residues comprising the IVR domain using the web-based
I-TASSER platform service [97–99], and found that it is com-
prised of nine α-helices (figure 4). The basic amino acids
adjacent to C273 (i.e. R272 and H274) and C288 (i.e. K287)
are expected to cause the deprotonation of the cysteine thiol
groups, hence increasing their reactivity.
The Kelch domain of KEAP1 is evolutionarily conserved
and contains nine cysteine residues at amino acid positions
319, 368, 395, 406, 434, 489, 513, 518 and 583. The first crystal
structure of theKEAP1Kelch domainwas solved at a resolution
of 1.85Å in 2004 byLi and colleagues [100]. Several crystal struc-
tures of both the human and murine KEAP1 Kelch domains
with different resolutions and in combination with compounds
or short peptide sequences of the Neh2 domain of NRF2 have
since been reported [101–107]. The Kelch domain in KEAP1
contains six Kelch repeats that assemble into a six-bladed β-pro-
peller structure (blades I-VI), where the C-terminal residues
form the first strand in the first blade (figure 1b). Four-stranded
antiparallel β-sheets form one blade, where the shortest β-sheet
is found at the central core [100,108]. The Kelch domain also
contains double glycine repeats (DGR), which are located at
the terminal end of the β-sheets.
First discovered in the laboratory of Masayuki Yamamoto
in 1999 by Itoh and colleagues, the N-terminal Neh2 domain
within NRF2 has been since reported by various groups to
bind to the KEAP1 Kelch domain [56]. Using nuclear mag-
netic resonance spectroscopy, Tong et al. discovered that the
Neh2 domain was intrinsically disordered [26]. It was sub-
sequently found that the evolutionarily conserved DLG
[109] and ETGE [56] motifs within the NRF2-Neh2 domain
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CYS 151
HIS 129
HIS 154
LYS 150
8.874 Å
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7.883 Å
6.266 Å
3.562 Å
5.609 Å
5.745 Å
LYS 131
ARG 135
CYS 151
(b)(a)
Figure 3. Structure of the human KEAP1 BTB domain. (a) Cartoon representation of the human KEAP1 BTB domain ( pale pink) showing the side chain of CYS 151 in
green. (b) The side chains of the basic amino acids (HIS 129, LYS 131, ARG 135, LYS 150 and HIS 154) adjacent to and surrounding the CYS 151 residues are
represented with green stick drawings coloured by their elements. Structure drawn using UCSF ChimeraX software using the PDB accession 4CXI. The distances
have been calculated in angstroms (Å) between these basic residues and CYS 151.
CYS 288
CYS 273
HIS 274
ARG 272
LYS 287
Figure 4. Modelled structure of the human KEAP1 IVR domain. Cartoon rep-
resentation of the I-TASSER program modelled human KEAP1 IVR domain
displaying 9 α-helices (grey). The basic amino acids (ARG 272 and HIS
274, green) found adjacent to the CYS 273 residue ( pink) as well as the
hydrophobic LYS 287 (green) residue found adjacent to CYS 288 ( pink)
where their side chains are represented with stick drawings coloured by
their respective elements. The structure was drawn with UCSF ChimeraX
software.
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7(figure 1a) were responsible for binding to the KEAP1 Kelch
domains [26,110]. Compared with the ETGE motif, the DLG
motif has a 200-fold lower affinity for the Kelch domain of
KEAP1 [102]. The DLG and ETGE motifs flank a lysine-rich
α-helix to allow for the conjugation of ubiquitin molecules
by the activated ubiquitin conjugating E2 enzyme. Attach-
ment of NRF2 to KEAP1 via both of these motifs is
required for ubiquitination of the transcription factor, and a
‘fixed-ends’ or a ‘hinge-and-latch’ model for NRF2 ubiquity-
lation was proposed, where each binding motif of one
molecule of NRF2 is tethered to a separate subunit of the
KEAP1 homodimer [110,111]. Based on this knowledge, the
Kelch domain of KEAP1 has become the target for the devel-
opment of non-electrophilic NRF2 activators, which function
as PPI inhibitors [112]. One example includes a series of 1,4-
diphenyl-1,2,3-triazole compounds, which have been shown
to disrupt the KEAP1:NRF2 PPIs in vitro using a fluorescence
polarization assay, as well as in live cells expressing EGFP-NRF2 and KEAP1-mCherry fusion proteins using a Förster
resonance energy transfer-based system and multiphoton flu-
orescence lifetime imaging microscopy [113].
The C-terminal domain of KEAP1 is the home of three of
the four cysteine sensors of KEAP1, which are used redun-
dantly to mediate NRF2 activation in response to hydrogen
peroxide (H2O2), the major ROS in redox regulation of biologi-
cal processes. Very recently, Suzuki et al. [77] generated a
construct for mammalian cell expression of a KEAP1 mutant,
which lacks 11 out of the 25 cysteine residues of the murine
protein. This mutant KEAP1 was still able to target NRF2 for
ubiquitination and proteasomal degradation, but was unable
to respond tomost cysteine-reactiveNRF2 activators, including
H2O2. A series of elegant experiments involving mouse
embryonic fibroblast cells expressing various KEAP1 cysteine
mutants as well as five distinct KEAP1 mutant mouse lines
revealed that KEAP1 uses C226, C613, C622 and C624
redundantly to sense H2O2 [77].
Although no crystal structure of full-length KEAP1 is
available to date, a 24 Å resolution reconstituted electron
microscopy (EM) structure has been described [114]. It shows
that the KEAP1 dimer resembles a cherry-bob, where two
large spheres, corresponding to theKelch domains, are attached
by short linker arms. Interestingly, each IVR domain surrounds
the core of the Kelch domain, suggesting that chemical modifi-
cations of cysteines within the IVR domains may affect the
KEAP1–NRF2 interactions through the Kelch domains.
3.2. KEAP1-CUL3 interaction
The primary system for protein degradation in the cell is the
ubiquitin-proteasome system, where E3 ubiquitin ligases are
essential components. Cullins are a family of hydrophobic pro-
teins that confer substrate specificity by acting as scaffolds for
E3 ubiquitin ligase complexes [115,116]. Thus far, in mammals,
there have been sevenCullins (1, 2, 3, 4A, 4B, 5 and 7) identified.
CUL3 is the only member of its family that is able to recognize
BTB domains-containing proteins [116]. Since KEAP1 contains
BTB domains, in 2004, Kobayashi and colleagues hypothesized
that under basal conditions, CUL3 could be mediating the
degradation of NRF2 through binding of the substrate adaptor
KEAP1 [93]. Indeed, three independent groups simultaneously
(b)(a)
(c) (d ) (e)
Figure 5. Chemical structures of selected cyclic cyanoenone NRF2 activators.
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8discovered that KEAP1 forms a functional E3 ubiquitin ligase
complex with CUL3/RBX1 [93,117,118]. Shortly after, Furu-
kawa & Xiong reported that KEAP1 and CUL3 binding
occurs between the BTB-domain of the former and the N-term-
inal domain of the latter [119]. Subsequently, it was discovered
that CUL3 homodimerization requires the presence of its N-
terminal domain and is dependent on its interaction with BTB
domain-containing substrates (e.g. KEAP1) which also are
able to homodimerize at their BTB domains [120].4. The cyclic cyanoenones, the most potent
class of NRF2 activators
To date, the cyanoenone triterpenoids are the most potent
NRF2 activators known. They were designed and developed
starting from the natural product oleanolic acid [121–123],
and new generations of analogues have been synthesized
[124]. These semi-synthetic compounds are highly electrophi-
lic, bind covalently and reversibly to sulfhydryl groups [125],
and have favourable pharmacokinetic and pharmacodynamic
profiles in vivo, including in humans [126–128]. Currently,
two cyanoenone triterpenoids are in clinical trials led by
Reata Pharmaceuticals (USA) and Kyowa Hakko Kirin
(Japan) for the treatment of diseases, which have been linked
with chronic inflammation and abnormal redox homeostasis.
One is CDDO-Me (2-cyano-3,12-dioxooleana-1,9(11)-dien-28-
oic acid methyl ester; bardoxolone methyl, figure 5a) for the
treatment of connective tissue disease–pulmonary arterial
hypertension, pulmonary hypertension, Alport’s syndrome,
polycystic kidney disease, renal insufficiency and liver disease.
The other is RTA-408 (omaveloxolone, figure 5b) for the treat-
ment of Friedreich’s ataxia, mitochondrial myopathy, ocular
inflammation, ocular pain, corneal endothelial cell loss, catar-
act surgery, melanoma and radiation dermatitis in breast
cancer patients [23]. Recently, Reata Pharmaceuticals reported
the evaluation of the pharmacokinetics and tissue distribution
of orally administered RTA-408 to cynomolgus monkeys after
single and multiple oral doses, and the initial results from aclinical trial in Friedreich’s ataxia patients [126]. Dose-depen-
dent plasma levels of RTA-408 and induction of NRF2 target
genes were detected in peripheral blood mononuclear cells,
liver, lung, and brain of the animals. In patients, improvements
in neurological functions were observed at doses of 80 mg or
greater; these doses resulted in plasma drug concentrations
consistent with those inducing NRF2 target genes in animals.
To improve their potencies as anti-inflammatory agents
and understand the details of their mechanism of action,
numerous pentacyclic, tricyclic and monocyclic compounds
containing cyanoenone functionalities were designed, syn-
thesized and tested for their anti-inflammatory and NRF2-
inducing activities in a programme of work led by Michael
Sporn, Gordon Gribble, Tadashi Honda and Karen Liby at
Dartmouth College [121,129–131]. In collaboration with the
laboratory of Paul Talalay, these researchers found a linear cor-
relation ranging over six orders ofmagnitude of concentrations
between the potencies of 18 pentacyclic derivatives to inhibit
inducible nitric oxide synthase (iNOS) and to activate the pro-
totypic NRF2 target enzyme NQO1 [132]. Subsequently, this
correlation was confirmed more broadly, for all main classes
of NRF2 activators [133]. The high potency of the triterpenoid
analogues in inducing NRF2 and inhibiting inflammation
requires the presence of activated Michael reaction (enone)
functions at critical positions in rings A and/or C. Among
the cyclic cyanoenone derivatives, the acetylenic tricyclic
bis(cyanoenone) TBE-31 is an exceptionally potent inducer
(figure 5c). TBE-31 is active at sub- to low-nanomolar concen-
trations, with Concentration that Doubles the specific enzyme
activity of NQO1 in murine Hepa1c1c7 cells (CD value) of
0.9 nM [134–137]. This compound is highly bioavailable and
suitable for chronic oral administration [138,139]. The presence
of two cyanoenone functionalities (in rings A and C) integrated
in a three-ring structure confers particularly high inducer
potency [138]. Another tricyclic cyanoenone, MCE-23 contains
an identical ring C present in TBE-31, however, it does not have
the cyanoenone moiety in its ring A (figure 5d ), and is
comparatively less potent, with a CD value of 41 nM [140].
MCE-1, a monocyclic cyanoenone (figure 5e), contains the
royalsocietypublishing.org/journal/rsob
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9ring C of MCE-23 and TBE-31. Similar to MCE-23 and TBE-31,
MCE-1 also inducesNQO1 (CD= 22 nM) [131,138]. All of these
cyanoenones exhibit anti-inflammatory activity in RAW 264.7
cells as well as primary macrophage (PMΦ) cells derived
from mice [131,138]. Furthermore, in a murine inflammation-
mediated depression model, MCE-1 and TBE-31 exhibit
anti-depressant effects [141].
CDDO-Me, RTA-408, MCE-1, MCE-23 and TBE-31 possess
electrophilic Michael acceptor(s) within their chemical struc-
tures, and are therefore extremely reactive with sulfhydryl
groups. Early studies employing ultraviolet–visible (UV-VIS)
spectroscopy had shown that compounds of this class react
with cysteines in KEAP1, but the identity of the specific
cysteine sensor(s) within the protein was not known
[132,136]. In collaboration with Takafumi Suzuki and
Masayuki Yamamoto (Tohoku University), we generated
KEAP1-knockout mouse embryonic fibroblast (MEF) cells
that were reinstated with wild-type or various cysteine
mutants of KEAP1, and monitored the stabilization of NRF2
upon exposure to cyanoenones [70]. In addition, we isolated
PMΦ cells from wild-type KEAP1 (KEAP+/+) or the knock-in
mutant KEAP-C151S (KEAPC151S/C151S) mice, whichwere gen-
erated by use of the CRISPR/Cas9 technology. This study
revealed that C151 is the primary sensor for the cyanoenone
class of NRF2 inducers, irrespective of their molecular shape
or size. Furthermore, C151S mutation in KEAP1 (i.e. in the
KEAP1C151S/C151S PMΦ cells) not only abolished the inducer
activity of low concentrations of TBE-31, but it also diminished
its anti-inflammatory activity. This effect was confirmed
using transgenic mice expressing human interleukin 6 (IL-6)-
luciferase reporter that were either KEAP1 wild-type or
KEAPC151S/C151S mutant. Taken together, these experiments
highlight the anti-inflammatory effect of NRF2 activation.
It is noteworthy that, although C151 is the primary sensor
for the cyanoenone class of NRF2 inducers, the concentration
of the inducer is critical for on-target selectivity. Thus, at low
cyanoenone concentrations, C151 is essential for NRF2 stabil-
ization, however, at higher cyanoenone concentrations, NRF2
stabilization proceeds in the absence of C151 [70]. These find-
ings underscore the importance of the inherent flexibility of
the sensor cysteines in KEAP1, explain the apparent discre-
pancies between the results from some of the published
studies, and highlight the immense importance of determin-
ing the accurate dose of even the most selective electrophilic
NRF2 inducer for achieving on-target selectivity.
Because RTA-408 can cross the blood–brain barrier and is
currently in clinical development [23], its disease-modifyingefficacy was tested in a rat model of status epilepticus, a dis-
ease, where cytotoxicity and inflammation constitute major
pathogenic drivers. In a study led by Matthew Walker,
Andrey Abramov and their colleagues at University College
London, it was found that 3 daily doses of RTA-408 given in
the first week of established disease potently inhibited epilep-
togenesis during the subsequent 12 weeks, and preserved both
neurons and astrocytes in the hippocampus of the animals [71].
This remarkable effect indicates that breaking the vicious circle
of redox imbalance causing macromolecular damage and cell
death triggering inflammation leading to neuronal death and
seizures, which in turn cause more neuronal death and greater
inflammation, and more seizures, can be highly effective in
managing this disease. Most importantly, the unprecedented
high efficacyof RTA-408 in thismodel, and the fact that it is cur-
rently in clinical trials, suggests the potential for this drug as a
disease-modifying treatment in epilepsy and perhaps other
neurological conditions.5. Concluding remarks
The extraordinary ability of KEAP1 to sense a multitude of
inducers that vary in shape, size and reactivity, and are able
to ‘read’ an intricately complex ‘cysteine code’, coupled with
its intrinsic flexibility, guarantees a finely tuned, and tightly
regulated antioxidant response. More than two decades of
research conducted by numerous independent groups of inves-
tigators has convincingly demonstrated that the ability to
mount this cytoprotective response is critical for adaptation
and survival, and can be exploited to protect against or delay
the onset of pathological processes, particularly those that
involve oxidative stress and inflammation. Indeed, KEAP1 is
the target of several small-molecule NRF2 activators, which
are currently in clinical trials and hold promise for the preven-
tion and treatment of chronic disease.Data accessibility. This article has no additional data.
Competing interests. A.T.D-K. is a member of the Scientific Advisory
Board of Evgen Pharma and a consultant for Aclipse Therapeutics
and Vividion Therapeutics.
Funding. We thank Cancer Research UK (C20953/A18644) and Reata
Pharmaceuticals for financial support.
Acknowledgements. We are immensely grateful to Michael Sporn,
Gordon Gribble, Tadashi Honda and Karen Liby (Dartmouth Col-
lege, USA) for introducing us to the cyanoenone class of NRF2
activators and most enjoyable collaborative interactions.References1. Sies H, Jones DP. In press. Reactive oxygen species
(ROS) as pleiotropic physiological signalling agents.
Nat. Rev. Mol. Cell Biol. (doi:10.1038/s41580-020-
0230-3)
2. Sies H. 2015 Oxidative stress: a concept in redox
biology and medicine. Redox Biol. 4, 180–183.
(doi:10.1016/j.redox.2015.01.002)
3. Andersen JK. 2004 Oxidative stress in
neurodegeneration: cause or consequence? Nat.
Med. 10, S18-S25. (doi:10.1038/nrn1434)4. Fukui H, Moraes CT. 2008 The mitochondrial
impairment, oxidative stress and neurodegeneration
connection: reality or just an attractive hypothesis?
Trends Neurosci. 31, 251–256. (doi:10.1016/j.tins.
2008.02.008)
5. Mahalingaiah PK, Ponnusamy L, Singh KP. 2015
Chronic oxidative stress causes estrogen-
independent aggressive phenotype, and
epigenetic inactivation of estrogen receptor
alpha in MCF-7 breast cancer cells. BreastCancer Res. Treat. 153, 41–56. (doi:10.1007/s10549-
015-3514-0)
6. Mehlman MA. 1992 Dangerous and cancer-causing
properties of products and chemicals in the oil
refining and petrochemical industry. VIII. Health
effects of motor fuels: carcinogenicity of gasoline–
scientific update. Environ. Res. 59, 238–249.
(doi:10.1016/S0013-9351(05)80243-9)
7. Ceriello A. 2006 Oxidative stress and
diabetes-associated complications. Endocr
royalsocietypublishing.org/journal/rsob
Open
Biol.10:200105
10Pract. 12(Suppl. 1), 60–62. (doi:10.4158/EP.
12.S1.60)
8. Bravi MC, Armiento A, Laurenti O, Cassone-Faldetta
M, De Luca O, Moretti A, De Mattia G. 2006 Insulin
decreases intracellular oxidative stress in patients
with type 2 diabetes mellitus. Metabolism 55,
691–695. (doi:10.1016/j.metabol.2006.01.003)
9. Ramani S, Pathak A, Dalal V, Paul A, Biswas S. In
press. Oxidative stress in autoimmune diseases: an
under dealt malice. Curr. Protein Pept Sci. (doi:10.
2174/1389203721666200214111816)
10. Rinnerthaler M, Bischof J, Streubel MK, Trost A,
Richter K. 2015 Oxidative stress in aging human
skin. Biomolecules 5, 545–589. (doi:10.3390/
biom5020545)
11. Kruk J, Duchnik E. 2014 Oxidative stress and skin
diseases: possible role of physical activity. Asian
Pac. J. Cancer Prev. 15, 561–568. (doi:10.7314/
apjcp.2014.15.2.561)
12. Okayama Y. 2005 Oxidative stress in allergic and
inflammatory skin diseases. Curr. Drug Targets
Inflamm. Allergy 4, 517–519. (doi:10.2174/
1568010054526386)
13. Hector A, Griese M, Hartl D. 2014 Oxidative stress in
cystic fibrosis lung disease: an early event, but
worth targeting? Eur. Respir. J. 44, 17–19. (doi:10.
1183/09031936.00038114)
14. Bast A, Weseler AR, Haenen GR, den Hartog GJ.
2010 Oxidative stress and antioxidants in interstitial
lung disease. Curr. Opin Pulm. Med. 16, 516–520.
(doi:10.1097/MCP.0b013e32833c645d)
15. Costa S, Reina-Couto M, Albino-Teixeira A, Sousa T.
2016 Statins and oxidative stress in chronic heart
failure. Rev. Port. Cardiol. 35, 41–57. (doi:10.1016/j.
repc.2015.09.006)
16. Ivanov AV, Bartosch B, Isaguliants MG. 2017
Oxidative stress in infection and consequent disease.
Oxid. Med. Cell Longev. 2017, 3496043. (doi:10.
1155/2017/3496043)
17. Muntane J, Puig-Parellada P, Mitjavila MT. 1995
Iron metabolism and oxidative stress during acute
and chronic phases of experimental inflammation:
effect of iron-dextran and deferoxamine. J. Lab. Clin.
Med. 126, 435–443.
18. Liguori I et al. 2018 Oxidative stress, aging, and
diseases. Clin. Interv. Aging. 13, 757–772. (doi:10.
2147/CIA.S158513)
19. Fukagawa NK. 1999 Aging: is oxidative stress a
marker or is it causal? Proc. Soc. Exp. Biol.
Med. 222, 293–298. (doi:10.1046/j.1525-1373.
1999.d01-146.x)
20. Joseph JA, Roth GS. 1992 Cholinergic systems in
aging: the role of oxidative stress. Clin.
Neuropharmacol. 15(Suppl 1 Pt A), 508A-509A.
(doi:10.1097/00002826-199201001-00264)
21. Hayes JD, Dinkova-Kostova AT. 2014 The Nrf2
regulatory network provides an interface between
redox and intermediary metabolism. Trends
Biochem. Sci. 39, 199–218. (doi:10.1016/j.tibs.
2014.02.002)
22. Dinkova-Kostova AT, Kostov RV, Canning P.
2017 Keap1, the cysteine-based mammalian
intracellular sensor for electrophiles and oxidants.Arch. Biochem. Biophys. 617, 84–93. (doi:10.1016/j.
abb.2016.08.005)
23. Cuadrado A et al. 2019 Therapeutic targeting of the
NRF2 and KEAP1 partnership in chronic diseases.
Nat. Rev. Drug Discov. 18, 295–317. (doi:10.1038/
s41573-018-0008-x)
24. Baird L, Lleres D, Swift S, Dinkova-Kostova AT. 2013
Regulatory flexibility in the Nrf2-mediated stress
response is conferred by conformational cycling of
the Keap1-Nrf2 protein complex. Proc. Natl Acad.
Sci. USA 110, 15 259–15 264. (doi:10.1073/pnas.
1305687110)
25. Baird L, Dinkova-Kostova AT. 2013 Diffusion
dynamics of the Keap1-Cullin3 interaction in single
live cells. Biochem. Biophys. Res. Commun. 433,
58–65. (doi:10.1016/j.bbrc.2013.02.065)
26. Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T,
Yamamoto M. 2006 Keap1 recruits Neh2 through
binding to ETGE and DLG motifs: characterization of
the two-site molecular recognition model. Mol. Cell
Biol. 26, 2887–2900. (doi:10.1128/MCB.26.8.2887-
2900.2006)
27. Dodson M, de la Vega MR, Cholanians AB,
Schmidlin CJ, Chapman E, Zhang DD.
2019 Modulating NRF2 in disease: timing is
everything. Annu. Rev. Pharmacol. Toxicol. 59,
555–575. (doi:10.1146/annurev-pharmtox-
010818-021856)
28. Tonelli C, Chio II. C., Tuveson DA. 2018
Transcriptional regulation by Nrf2. Antioxid Redox
Signal. 29, 1727–1745. (doi:10.1089/ars.2017.7342)
29. Lu SC. 2009 Regulation of glutathione synthesis.
Mol. Aspects Med. 30, 42–59. (doi:10.1016/j.mam.
2008.05.005)
30. Teskey G et al. 2018 Glutathione as a marker for
human disease. Adv. Clin. Chem. 87, 141–159.
(doi:10.1016/bs.acc.2018.07.004)
31. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. 2004
Glutathione metabolism and its implications for
health. J. Nutr. 134, 489–492. (doi:10.1093/jn/134.
3.489)
32. Wild AC, Mulcahy RT. 2000 Regulation of gamma-
glutamylcysteine synthetase subunit gene
expression: insights into transcriptional control of
antioxidant defenses. Free Radic. Res. 32, 281–301.
(doi:10.1080/10715760000300291)
33. Sasaki H et al. 2002 Electrophile response element-
mediated induction of the cystine/glutamate
exchange transporter gene expression. J. Biol. Chem.
277, 44 765–44 771. (doi:10.1074/jbc.M208704200)
34. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T,
Nukiwa T, Aburatani H, Yamamoto M, Motohashi H.
2012 Nrf2 redirects glucose and glutamine into
anabolic pathways in metabolic reprogramming.
Cancer Cell 22, 66–79. (doi:10.1016/j.ccr.
2012.05.016)
35. Hirotsu Y, Katsuoka F, Funayama R, Nagashima T,
Nishida Y, Nakayama K, Engel JD, Yamamoto M.
2012 Nrf2-MafG heterodimers contribute globally to
antioxidant and metabolic networks. Nucleic Acids
Res. 40, 10 228–10 239. (doi:10.1093/nar/gks827)
36. Singh A et al. 2013 Transcription factor NRF2
regulates miR-1 and miR-206 to drivetumorigenesis. J. Clin. Invest. 123, 2921–2934.
(doi:10.1172/JCI66353)
37. Vargas MR, Johnson DA, Sirkis DW, Messing A,
Johnson JA. 2008 Nrf2 activation in astrocytes
protects against neurodegeneration in mouse
models of familial amyotrophic lateral sclerosis.
J. Neurosci. 28, 13 574–13 581. (doi:10.1523/
JNEUROSCI.4099-08.2008)
38. Cuadrado A, Moreno-Murciano P, Pedraza-Chaverri J.
2009 The transcription factor Nrf2 as a new
therapeutic target in Parkinson’s disease. Expert
Opin. Ther. Targets. 13, 319–329. (doi:10.1517/
13543780802716501)
39. Schousboe A, Scafidi S, Bak LK, Waagepetersen HS,
McKenna MC. 2014 Glutamate metabolism in the
brain focusing on astrocytes. Adv. Neurobiol. 11,
13–30. (doi:10.1007/978-3-319-08894-5_2)
40. Bell KF et al. 2015 Neuronal development is
promoted by weakened intrinsic antioxidant
defences due to epigenetic repression of Nrf2. Nat.
Commun. 6, 7066. (doi:10.1038/ncomms8066)
41. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson
DA, Kan YW, Johnson JA. 2009 Nrf2-mediated
neuroprotection in the MPTP mouse model of
Parkinson’s disease: critical role for the astrocyte.
Proc. Natl Acad. Sci. USA 106, 2933–2938. (doi:10.
1073/pnas.0813361106)
42. Sayin VI et al. 2017 Activation of the NRF2
antioxidant program generates an imbalance in
central carbon metabolism in cancer. Elife 6,
e28083. (doi:10.7554/eLife.28083)
43. Liu H, Zimmerman AW, Singh K, Connors SL,
Diggins E, Stephenson KK, Dinkova-Kostova AT,
Fahey JW. 2020 Biomarker exploration in human
peripheral blood mononuclear cells for monitoring
sulforaphane treatment responses in autism
spectrum disorder. Sci. Rep. 10, 5822. (doi:10.1038/
s41598-020-62714-4)
44. Bambouskova M et al. 2018 Electrophilic properties
of itaconate and derivatives regulate the
IkappaBzeta-ATF3 inflammatory axis. Nature 556,
501–504. (doi:10.1038/s41586-018-0052-z)
45. Mills EL et al. 2018 Itaconate is an anti-
inflammatory metabolite that activates Nrf2 via
alkylation of KEAP1. Nature 556, 113–117. (doi:10.
1038/nature25986)
46. Kobayashi EH et al. 2016 Nrf2 suppresses
macrophage inflammatory response by blocking
proinflammatory cytokine transcription. Nat.
Commun. 7, 11624. (doi:10.1038/ncomms11624)
47. Kong X, Thimmulappa R, Craciun F, Harvey C, Singh
A, Kombairaju P, Reddy SP, Remick D, Biswal S.
2011 Enhancing Nrf2 pathway by disruption of
Keap1 in myeloid leukocytes protects against sepsis.
Am. J. Respir. Crit. Care Med. 184, 928–938.
(doi:10.1164/rccm.201102-0271OC)
48. Olagnier D et al. 2017 Activation of Nrf2 signaling
augments vesicular stomatitis virus oncolysis via
autophagy-driven suppression of antiviral immunity.
Mol. Ther. 25, 1900–1916. (doi:10.1016/j.ymthe.
2017.04.022)
49. Thimmulappa RK, Lee H, Rangasamy T, Reddy SP,
Yamamoto M, Kensler TW, Biswal S. 2006 Nrf2 is a
royalsocietypublishing.org/journal/rsob
Open
Biol.10:200105
11critical regulator of the innate immune response
and survival during experimental sepsis. J. Clin.
Invest. 116, 984–995. (doi:10.1172/JCI25790)
50. Baardman J et al. 2018 A defective pentose
phosphate pathway reduces inflammatory
macrophage responses during hypercholesterolemia.
Cell Rep. 25, 2044–2052. (doi:10.1016/j.celrep.2018.
10.092)
51. Cuadrado A et al. 2018 Transcription factor NRF2 as
a therapeutic target for chronic diseases: a systems
medicine approach. Pharmacol. Rev. 70, 348–383.
(doi:10.1124/pr.117.014753)
52. Sporn MB, Liby KT. 2012 NRF2 and cancer: the
good, the bad and the importance of context. Nat.
Rev. Cancer. 12, 564–571. (doi:10.1038/nrc3278)
53. Robledinos-Anton N, Fernandez-Gines R, Manda G,
Cuadrado A. 2019 Activators and inhibitors of NRF2:
a review of their potential for clinical development.
Oxid. Med. Cell. Longev. 2019, 9372182. (doi:10.
1155/2019/9372182)
54. Prochaska HJ, De Long MJ, Talalay P. 1985 On the
mechanisms of induction of cancer-protective
enzymes: a unifying proposal. Proc. Natl Acad. Sci.
USA 82, 8232–8236. (doi:10.1073/pnas.82.23.8232)
55. Talalay P, De Long MJ, Prochaska HJ. 1988
Identification of a common chemical signal
regulating the induction of enzymes that
protect against chemical carcinogenesis. Proc. Natl
Acad. Sci. USA 85, 8261–8265. (doi:10.1073/pnas.
85.21.8261)
56. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K,
Engel JD, Yamamoto M. 1999 Keap1 represses
nuclear activation of antioxidant responsive
elements by Nrf2 through binding to the amino-
terminal Neh2 domain. Genes Dev. 13, 76–86.
(doi:10.1101/gad.13.1.76)
57. Marino SM, Gladyshev VN. 2012 Analysis and
functional prediction of reactive cysteine residues.
J. Biol. Chem. 287, 4419–4425. (doi:10.1074/jbc.
R111.275578)
58. Roos G, Foloppe N, Messens J. 2013 Understanding
the pK(a) of redox cysteines: the key role of
hydrogen bonding. Antioxid Redox Signal. 18,
94–127. (doi:10.1089/ars.2012.4521)
59. Gould NS, Evans P, Martinez-Acedo P, Marino SM,
Gladyshev VN, Carroll KS, Ischiropoulos H. 2015 Site-
specific proteomic mapping identifies selectively
modified regulatory cysteine residues in functionally
distinct protein networks. Chem. Biol. 22, 965–975.
(doi:10.1016/j.chembiol.2015.06.010)
60. Snyder GH, Cennerazzo MJ, Karalis AJ, Field D. 1981
Electrostatic influence of local cysteine environments
on disulfide exchange kinetics. Biochemistry 20,
6509–6519. (doi:10.1021/bi00526a001)
61. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K,
Wakabayashi N, Katoh Y, Yamamoto M, Talalay P.
2002 Direct evidence that sulfhydryl groups of
Keap1 are the sensors regulating induction of phase
2 enzymes that protect against carcinogens and
oxidants. Proc. Natl Acad. Sci. USA 99, 11 908–
11 913. (doi:10.1073/pnas.172398899)
62. Zipper LM, Mulcahy RT. 2002 The Keap1 BTB/POZ
dimerization function is required to sequester Nrf2in cytoplasm. J. Biol. Chem. 277, 36 544–36 552.
(doi:10.1074/jbc.M206530200)
63. Zhang DD, Hannink M. 2003 Distinct cysteine
residues in Keap1 are required for Keap1-dependent
ubiquitination of Nrf2 and for stabilization of Nrf2
by chemopreventive agents and oxidative stress.
Mol. Cell. Biol. 23, 8137–8151. (doi:10.1128/mcb.
23.22.8137-8151.2003)
64. McMahon M, Lamont DJ, Beattie KA, Hayes JD.
2010 Keap1 perceives stress via three sensors for the
endogenous signaling molecules nitric oxide, zinc,
and alkenals. Proc. Natl Acad. Sci. USA. 107,
18 838–18 843. (doi:10.1073/pnas.1007387107)
65. Saito R et al. 2015 Characterizations of three major
cysteine sensors of keap1 in stress response. Mol.
Cell Biol. 36, 271–284. (doi:10.1128/MCB.00868-15)
66. Zhang DD, Lo SC, Sun Z, Habib GM, Lieberman MW,
Hannink M. 2005 Ubiquitination of Keap1, a BTB-
Kelch substrate adaptor protein for Cul3, targets
Keap1 for degradation by a proteasome-
independent pathway. J. Biol. Chem. 280,
30 091–30 099. (doi:10.1074/jbc.M501279200)
67. Fourquet S, Guerois R, Biard D, Toledano MB. 2010
Activation of NRF2 by nitrosative agents and H2O2
involves KEAP1 disulfide formation. J. Biol. Chem.
285, 8463–8471. (doi:10.1074/jbc.M109.051714)
68. Bollong MJ et al. 2018 A metabolite-derived protein
modification integrates glycolysis with KEAP1-NRF2
signalling. Nature 562, 600–604. (doi:10.1038/
s41586-018-0622-0)
69. Xue M et al. 2012 Transcriptional control of
glyoxalase 1 by Nrf2 provides a stress-responsive
defence against dicarbonyl glycation. Biochem. J.
443, 213–222. (doi:10.1042/BJ20111648)
70. Dayalan Naidu S et al. 2018 C151 in KEAP1 is the
main cysteine sensor for the cyanoenone class of
NRF2 activators, irrespective of molecular size or
shape. Sci. Rep. 8, 8037. (doi:10.1038/s41598-018-
26269-9)
71. Shekh-Ahmad T, Eckel R, Dayalan Naidu S, Higgins
M, Yamamoto M, Dinkova-Kostova AT, Kovac S,
Abramov AY, Walker MC. 2018 KEAP1 inhibition is
neuroprotective and suppresses the development of
epilepsy. Brain 141, 1390–1403. (doi:10.1093/
brain/awy071)
72. Cleasby A et al. 2014 Structure of the BTB domain
of Keap1 and its interaction with the triterpenoid
antagonist CDDO. PLoS ONE 9, e98896. (doi:10.
1371/journal.pone.0098896)
73. Takaya K, Suzuki T, Motohashi H, Onodera K, Satomi
S, Kensler TW, Yamamoto M. 2012 Validation of the
multiple sensor mechanism of the Keap1-Nrf2
system. Free Radic. Biol. Med. 53, 817–827. (doi:10.
1016/j.freeradbiomed.2012.06.023)
74. Hu C, Eggler AL, Mesecar AD, van Breemen RB.
2011 Modification of keap1 cysteine residues by
sulforaphane. Chem. Res. Toxicol. 24, 515–521.
(doi:10.1021/tx100389r)
75. Dayalan Naidu S, Suzuki T, Yamamoto M, Fahey JW,
Dinkova-Kostova AT. 2018 Phenethyl isothiocyanate,
a dual activator of transcription factors NRF2 and
HSF1. Mol. Nutr. Food Res. 62, e1700908. (doi:10.
1002/mnfr.201700908)76. Brennan MS, Matos MF, Li B, Hronowski X, Gao B,
Juhasz P, Rhodes KJ, Scannevin RH. 2015 Dimethyl
fumarate and monoethyl fumarate exhibit
differential effects on KEAP1, NRF2 activation, and
glutathione depletion in vitro. PLoS ONE 10,
e0120254. (doi:10.1371/journal.pone.0120254)
77. Suzuki T et al. 2019 Molecular mechanism of
cellular oxidative stress sensing by Keap1. Cell Rep.
28, 746–758. (doi:10.1016/j.celrep.2019.06.047)
78. Hourihan JM, Kenna JG, Hayes JD. 2013 The
gasotransmitter hydrogen sulfide induces Nrf2-
target genes by inactivating the Keap1 ubiquitin
ligase substrate adaptor through formation of a
disulfide bond between Cys-226 and Cys-613.
Antioxid Redox Signal. 19, 465–481. (doi:10.1089/
ars.2012.4944)
79. Kobayashi M et al. 2009 The antioxidant defense
system Keap1-Nrf2 comprises a multiple sensing
mechanism for responding to a wide range of
chemical compounds. Mol. Cell Biol. 29, 493–502.
(doi:10.1128/MCB.01080-08)
80. Fujii S et al. 2010 The critical role of nitric oxide
signaling, via protein S-guanylation and nitrated
cyclic GMP, in the antioxidant adaptive response.
J. Biol. Chem. 285, 23 970–23 984. (doi:10.1074/
jbc.M110.145441)
81. McMahon M, Swift SR, Hayes JD. 2018 Zinc-binding
triggers a conformational-switch in the cullin-3
substrate adaptor protein KEAP1 that controls
transcription factor NRF2. Toxicol. Appl. Pharmacol.
360, 45–57. (doi:10.1016/j.taap.2018.09.033)
82. Kumagai Y, Kanda H, Shinkai Y, Toyama T. 2013 The
role of the Keap1/Nrf2 pathway in the cellular
response to methylmercury. Oxid. Med. Cell Longev.
2013, 848279. (doi:10.1155/2013/848279)
83. Shinkai Y et al. 2015 Reactive sulfur species-
mediated activation of the Keap1-Nrf2 pathway by
1,2-Naphthoquinone through sulfenic acids
formation under oxidative stress. Chem. Res. Toxicol.
28, 838–847. (doi:10.1021/tx500416y)
84. Quinti L et al. 2017 KEAP1-modifying small
molecule reveals muted NRF2 signaling responses in
neural stem cells from Huntington’s disease
patients. Proc. Natl Acad. Sci. USA 114,
E4676-E4685. (doi:10.1073/pnas.1614943114)
85. Dietz BM et al. 2008 Angelica sinensis and its
alkylphthalides induce the detoxification enzyme
NAD(P)H: quinone oxidoreductase 1 by alkylating
Keap1. Chem. Res. Toxicol. 21, 1939–1948. (doi:10.
1021/tx8001274)
86. Kim S, Lee HG, Park SA, Kundu JK, Keum YS, Cha
YN, Na HK, Surh YJ. 2014 Keap1 cysteine 288 as a
potential target for diallyl trisulfide-induced Nrf2
activation. PLoS ONE 9, e85984. (doi:10.1371/
journal.pone.0085984)
87. Copple IM, Goldring CE, Jenkins RE, Chia AJ, Randle
LE, Hayes JD, Kitteringham NR, Park BK. 2008 The
hepatotoxic metabolite of acetaminophen directly
activates the Keap1-Nrf2 cell defense system.
Hepatology 48, 1292–1301. (doi:10.1002/
hep.22472)
88. Luo Y, Eggler AL, Liu D, Liu G, Mesecar AD, van
Breemen RB. 2007 Sites of alkylation of human
royalsocietypublishing.org/journal/rsob
Open
Biol.10:200105
12Keap1 by natural chemoprevention agents. J. Am.
Soc. Mass Spectrom. 18, 2226–2232. (doi:10.1016/j.
jasms.2007.09.015)
89. Hong F, Sekhar KR, Freeman ML, Liebler DC. 2005
Specific patterns of electrophile adduction trigger
Keap1 ubiquitination and Nrf2 activation. J. Biol.
Chem. 280, 31 768–31 775. (doi:10.1074/jbc.
M503346200)
90. Sakurai T, Kanayama M, Shibata T, Itoh K, Kobayashi
A, Yamamoto M, Uchida K. 2006 Ebselen, a seleno-
organic antioxidant, as an electrophile. Chem. Res.
Toxicol. 19, 1196–1204. (doi:10.1021/tx0601105)
91. Holland R, Hawkins AE, Eggler AL, Mesecar AD,
Fabris D, Fishbein JC. 2008 Prospective type 1 and
type 2 disulfides of Keap1 protein. Chem. Res.
Toxicol. 21, 2051–2060. (doi:10.1021/tx800226m)
92. Bryan HK, Olayanju A, Goldring CE, Park BK. 2013
The Nrf2 cell defence pathway: Keap1-dependent
and -independent mechanisms of regulation.
Biochem. Pharmacol. 85, 705–717. (doi:10.1016/j.
bcp.2012.11.016)
93. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke
Y, Chiba T, Igarashi K, Yamamoto M. 2004 Oxidative
stress sensor Keap1 functions as an adaptor for
Cul3-based E3 ligase to regulate proteasomal
degradation of Nrf2. Mol. Cell Biol. 24, 7130–7139.
(doi:10.1128/MCB.24.16.7130-7139.2004)
94. Wu JH, Miao W, Hu LG, Batist G. 2010 Identification
and characterization of novel Nrf2 inducers designed
to target the intervening region of Keap1. Chem.
Biol. Drug Des. 75, 475–480. (doi:10.1111/j.1747-
0285.2010.00955.x)
95. Levonen AL, Landar A, Ramachandran A, Ceaser EK,
Dickinson DA, Zanoni G, Morrow JD, Darley-Usmar
VM. 2004 Cellular mechanisms of redox cell
signalling: role of cysteine modification in
controlling antioxidant defences in response to
electrophilic lipid oxidation products. Biochem. J.
378, 373–382. (doi:10.1042/BJ20031049)
96. Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD,
Kang MI, Kobayashi A, Yamamoto M, Kensler TW,
Talalay P. 2004 Protection against electrophile and
oxidant stress by induction of the phase 2 response:
fate of cysteines of the Keap1 sensor modified by
inducers. Proc. Natl Acad. Sci. USA 101, 2040–2045.
(doi:10.1073/pnas.0307301101)
97. Zhang Y. 2009 I-TASSER: fully automated protein
structure prediction in CASP8. Proteins 77(Suppl. 9),
100–113. (doi:10.1002/prot.22588)
98. Roy A, Yang J, Zhang Y. 2012 COFACTOR: an accurate
comparative algorithm for structure-based protein
function annotation. Nucleic Acids Res. 40,
W471–W477. (doi:10.1093/nar/gks372)
99. Yang J, Zhang Y. 2015 I-TASSER server: new
development for protein structure and function
predictions. Nucleic Acids Res. 43, W174–W181.
(doi:10.1093/nar/gkv342)
100. Li X, Zhang D, Hannink M, Beamer LJ. 2004 Crystal
structure of the Kelch domain of human Keap1.
J. Biol. Chem. 279, 54 750–54 758. (doi:10.1074/
jbc.M410073200)
101. Lo SC, Li X, Henzl MT, Beamer LJ, Hannink M. 2006
Structure of the Keap1:Nrf2 interface providesmechanistic insight into Nrf2 signaling. EMBO J. 25,
3605–3617. (doi:10.1038/sj.emboj.7601243)
102. Tong KI, Padmanabhan B, Kobayashi A, Shang C,
Hirotsu Y, Yokoyama S, Yamamoto M. 2007
Different electrostatic potentials define ETGE and
DLG motifs as hinge and latch in oxidative stress
response. Mol. Cell Biol. 27, 7511–7521. (doi:10.
1128/MCB.00753-07)
103. Komatsu M et al. 2010 The selective autophagy
substrate p62 activates the stress responsive
transcription factor Nrf2 through inactivation of
Keap1. Nat. Cell Biol. 12, 213–223. (doi:10.1038/
ncb2021)
104. Fukutomi T, Takagi K, Mizushima T, Ohuchi N,
Yamamoto M. 2014 Kinetic, thermodynamic, and
structural characterizations of the association
between Nrf2-DLGex degron and Keap1. Mol. Cell
Biol. 34, 832–846. (doi:10.1128/MCB.01191-13)
105. Winkel AF et al. 2015 Characterization of RA839, a
noncovalent small molecule binder to Keap1 and
selective activator of Nrf2 signaling. J. Biol. Chem.
290, 28 446–28 455. (doi:10.1074/jbc.M115.
678136)
106. Davies TG et al. 2016 Monoacidic inhibitors of the
Kelch-like ECH-associated protein 1: nuclear factor
erythroid 2-related factor 2 (KEAP1:NRF2) protein-
protein interaction with high cell potency identified
by fragment-based discovery. J. Med. Chem. 59,
3991–4006. (doi:10.1021/acs.jmedchem.6b00228)
107. Saito T et al. 2016 p62/Sqstm1 promotes
malignancy of HCV-positive hepatocellular
carcinoma through Nrf2-dependent metabolic
reprogramming. Nat. Commun. 7, 12030. (doi:10.
1038/ncomms12030)
108. Canning P, Sorrell FJ, Bullock AN. 2015 Structural
basis of Keap1 interactions with Nrf2. Free Radic.
Biol. Med. 88, 101–107. (doi:10.1016/j.
freeradbiomed.2015.05.034)
109. McMahon M, Thomas N, Itoh K, Yamamoto M,
Hayes JD. 2004 Redox-regulated turnover of Nrf2 is
determined by at least two separate protein
domains, the redox-sensitive Neh2 degron and the
redox-insensitive Neh6 degron. J. Biol. Chem. 279,
31 556–31 567. (doi:10.1074/jbc.M403061200)
110. McMahon M, Thomas N, Itoh K, Yamamoto M,
Hayes JD. 2006 Dimerization of substrate adaptors
can facilitate cullin-mediated ubiquitylation of
proteins by a ‘tethering’ mechanism: a two-site
interaction model for the Nrf2-Keap1 complex.
J. Biol. Chem. 281, 24 756–24 768. (doi:10.1074/
jbc.M601119200)
111. Tong KI, Kobayashi A, Katsuoka F, Yamamoto M.
2006 Two-site substrate recognition model for the
Keap1-Nrf2 system: a hinge and latch mechanism.
Biol. Chem. 387, 1311–1320. (doi:10.1515/BC.
2006.164)
112. Wells G. 2015 Peptide and small molecule inhibitors
of the Keap1-Nrf2 protein-protein interaction.
Biochem. Soc. Trans. 43, 674–679. (doi:10.1042/
BST20150051)
113. Bertrand HC, Schaap M, Baird L, Georgakopoulos
ND, Fowkes A, Thiollier C, Kachi H, Dinkova-Kostova
AT, Wells G. 2015 Design, synthesis, and evaluationof triazole derivatives that induce Nrf2 dependent
gene products and inhibit the Keap1-Nrf2 protein-
protein interaction. J. Med. Chem. 58, 7186–7194.
(doi:10.1021/acs.jmedchem.5b00602)
114. Ogura T, Tong KI, Mio K, Maruyama Y, Kurokawa H,
Sato C, Yamamoto M. 2010 Keap1 is a forked-stem
dimer structure with two large spheres enclosing
the intervening, double glycine repeat, and C-
terminal domains. Proc. Natl Acad. Sci. USA 107,
2842–2847. (doi:10.1073/pnas.0914036107)
115. Sarikas A, Hartmann T, Pan ZQ. 2011 The cullin
protein family. Genome Biol. 12, 220. (doi:10.1186/
gb-2011-12-4-220)
116. Anderica-Romero AC, Gonzalez-Herrera IG,
Santamaria A, Pedraza-Chaverri J. 2013 Cullin 3 as a
novel target in diverse pathologies. Redox Biol. 1,
366–372. (doi:10.1016/j.redox.2013.07.003)
117. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA.
2004 The Keap1-BTB protein is an adaptor that
bridges Nrf2 to a Cul3-based E3 ligase: oxidative
stress sensing by a Cul3-Keap1 ligase. Mol. Cell Biol.
24, 8477–8486. (doi:10.1128/MCB.24.19.8477-
8486.2004)
118. Zhang HF, Tomida A, Koshimizu R, Ogiso Y, Lei S,
Tsuruo T. 2004 Cullin 3 promotes proteasomal
degradation of the topoisomerase I-DNA covalent
complex. Cancer Res. 64, 1114–1121. (doi:10.1158/
0008-5472.can-03-2858)
119. Furukawa M, Xiong Y. 2005 BTB protein Keap1
targets antioxidant transcription factor Nrf2 for
ubiquitination by the Cullin 3-Roc1 ligase. Mol. Cell
Biol. 25, 162–171. (doi:10.1128/MCB.25.1.162-171.
2005)
120. Choo YY, Hagen T. 2012 Mechanism of cullin3 E3
ubiquitin ligase dimerization. PLoS ONE 7, e41350.
(doi:10.1371/journal.pone.0041350)
121. Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM,
Gribble GW. 2011 New synthetic triterpenoids:
potent agents for prevention and treatment of
tissue injury caused by inflammatory and oxidative
stress. J. Nat. Prod. 74, 537–545. (doi:10.1021/
np100826q)
122. Honda T, Rounds BV, Bore L, Finlay HJ, Favaloro Jr
FG, Suh N, Wang Y, Sporn MB, Gribble GW. 2000
Synthetic oleanane and ursane triterpenoids with
modified rings A and C: a series of highly active
inhibitors of nitric oxide production in mouse
macrophages. J. Med. Chem. 43, 4233–4246.
(doi:10.1021/jm0002230)
123. Honda T, Honda Y, Favaloro Jr FG, Gribble GW, Suh
N, Place AE, Rendi MH, Sporn MB. 2002 A novel
dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-
1,9(11)-dien-28-onitrile, active at picomolar
concentrations for inhibition of nitric oxide
production. Bioorg. Med. Chem. Lett. 12,
1027–1030. (doi:10.1016/s0960-894x(02)00105-1)
124. Fu L, Lin QX, Onyango EO, Liby KT, Sporn MB,
Gribble GW. 2017 Design, synthesis, and biological
activity of second-generation synthetic oleanane
triterpenoids. Org. Biomol. Chem. 15, 6001–6005.
(doi:10.1039/c7ob01420a)
125. Couch RD, Browning RG, Honda T, Gribble GW,
Wright DL, Sporn MB, Anderson AC. 2005 Studies
royalsocietypublishing.org/journal/rsob
Open
Biol.10:200105
13on the reactivity of CDDO, a promising new
chemopreventive and chemotherapeutic agent:
implications for a molecular mechanism of action.
Bioorg. Med. Chem. Lett. 15, 2215–2219. (doi:10.
1016/j.bmcl.2005.03.031)
126. Reisman SA, Gahir SS, Lee CI, Proksch JW, Sakamoto
M, Ward KW. 2019 Pharmacokinetics and
pharmacodynamics of the novel Nrf2 activator
omaveloxolone in primates. Drug Des. Dev. Ther. 13,
1259–1270. (doi:10.2147/DDDT.S193889)
127. Lynch DR et al. 2019 Safety, pharmacodynamics,
and potential benefit of omaveloxolone in
Friedreich ataxia. Ann. Clin. Transl. Neurol. 6, 15–26.
(doi:10.1002/acn3.660)
128. Creelan BC et al. 2017 Safety, pharmacokinetics, and
pharmacodynamics of oral omaveloxolone (RTA
408), a synthetic triterpenoid, in a first-in-human
trial of patients with advanced solid tumors. Onco
Targets Ther. 10, 4239–4250. (doi:10.2147/OTT.
S136992)
129. Favaloro Jr FG, Honda T, Honda Y, Gribble GW, Suh
N, Risingsong R, Sporn MB. 2002 Design and
synthesis of tricyclic compounds with enone
functionalities in rings A and C: a novel class of
highly active inhibitors of nitric oxide production in
mouse macrophages. J. Med. Chem. 45, 4801–4805.
(doi:10.1021/jm025565f )
130. Honda T et al. 2011 Tricyclic compounds containing
nonenolizable cyano enones. A novel class of highly
potent anti-inflammatory and cytoprotective agents.
J. Med. Chem. 54, 1762–1778. (doi:10.1021/
jm101445p)131. Zheng S et al. 2012 Synthesis, chemical reactivity as
Michael acceptors, and biological potency of
monocyclic cyanoenones, novel and highly potent
anti-inflammatory and cytoprotective agents.
J. Med. Chem. 55, 4837–4846. (doi:10.1021/
jm3003922)
132. Dinkova-Kostova AT et al. 2005 Extremely potent
triterpenoid inducers of the phase 2 response:
correlations of protection against oxidant and
inflammatory stress. Proc. Natl Acad. Sci. USA 102,
4584–4589. (doi:10.1073/pnas.0500815102)
133. Liu H, Dinkova-Kostova AT, Talalay P. 2008
Coordinate regulation of enzyme markers for
inflammation and for protection against oxidants
and electrophiles. Proc. Natl Acad. Sci. USA 105,
15 926–15 931. (doi:10.1073/pnas.0808346105)
134. Yates MS et al. 2007 Pharmacodynamic
characterization of chemopreventive triterpenoids as
exceptionally potent inducers of Nrf2-regulated
genes. Mol. Cancer Ther. 6, 154–162. (doi:10.1158/
1535-7163.MCT-06-0516)
135. Honda T, Dinkova-Kostova AT, David E, Padegimas
EM, Sundararajan C, Visnick M, Bumeister R,
Christian Wigley W. 2011 Synthesis and biological
evaluation of 1-[2-cyano-3,12-dioxooleana-1,9(11)-
dien-28-oyl]-4-ethynylimidazole. A novel and
highly potent anti-inflammatory and cytoprotective
agent. Bioorg. Med. Chem. Lett. 21, 2188–2191.
(doi:10.1016/j.bmcl.2011.03.018)
136. Liby K et al. 2008 A novel acetylenic tricyclic bis-
(cyano enone) potently induces phase 2
cytoprotective pathways and blocks livercarcinogenesis induced by aflatoxin. Cancer Res. 68,
6727–6733. (doi:10.1158/0008-5472.CAN-08-1123)
137. Honda T, Sundararajan C, Yoshizawa H, Su X, Honda Y,
Liby KT, Sporn MB, Gribble GW. 2007 Novel tricyclic
compounds having acetylene groups at C-8a and
cyano enones in rings A and C: highly potent anti-
inflammatory and cytoprotective agents. J. Med.
Chem. 50, 1731–1734. (doi:10.1021/jm070141c)
138. Dinkova-Kostova AT et al. 2010 An exceptionally
potent inducer of cytoprotective enzymes:
elucidation of the structural features that determine
inducer potency and reactivity with Keap1. J. Biol.
Chem. 285, 33 747–33 755. (doi:10.1074/jbc.M110.
163485)
139. Kostov RV, Knatko EV, McLaughlin LA, Henderson CJ,
Zheng S, Huang JT, Honda T, Dinkova-Kostova AT.
2015 Pharmacokinetics and pharmacodynamics of
orally administered acetylenic tricyclic
bis(cyanoenone), a highly potent Nrf2 activator with
a reversible covalent mode of action. Biochem.
Biophys. Res. Commun. 465, 402–407. (doi:10.1016/
j.bbrc.2015.08.016)
140. Li W et al. 2015 New monocyclic, bicyclic, and
tricyclic ethynylcyanodienones as activators of the
Keap1/Nrf2/ARE pathway and inhibitors of inducible
nitric oxide synthase. J. Med. Chem. 58, 4738–4748.
(doi:10.1021/acs.jmedchem.5b00393)
141. Yao W et al. 2016 Antidepressant effects of TBE-31
and MCE-1, the novel Nrf2 activators, in an
inflammation model of depression.
Eur. J. Pharmacol. 793, 21–27. (doi:10.1016/j.
ejphar.2016.10.037)
